Promising new drug blocks mutation in bone marrow cancers

Dec 09, 2008

Oregon Health & Science University Knight Cancer Institute researchers have found that an experimental drug successfully blocks an enzyme that causes some bone marrow cancers.

The oral drug, called CYT387, was tested in mice as well as in human cells. In both cases, it blocked the growth of certain bone marrow cancers called myeloproliferative disorders, also referred to as MPDs.

The research will be presented Tuesday, Dec. 9, during the 50th annual American Society of Hematology conference in San Francisco.

"The drug was found to be very effective against a specific type of cancer cells, cancer cells which are driven by an enzyme mutation called JAK2-V617F. In the mouse model, the drug blocked JAK2-V617F, normalized blood counts and reduced enlarged spleens back to a normal size. It is a very promising compound," said Thomas Bumm, M.D., Ph.D., a member of the research team.

The drug works by binding to the V617F mutation in the JAK2 enzyme. Without this drug, the mutated JAK2 enzyme leads to MPDs. The "big three" MPDs include polycythemia vera, essential thrombocythemia and primary myelofibrosis. Until now there have been no FDA-approved targeted treatments for these diseases.

"Based on the efficacy that we demonstrated in the mouse model, there is a good chance that CYT387 will enter clinical trials as early as 2009. Those in greatest need include patients with myelofibrosis, a relentless disease for which there is currently no effective therapy. It is likely that JAK2 inhibitors will change the standard of care for these patients," said Michael Deininger, M.D., Ph.D., principal investigator and Head of the Hematological Malignancies Program Ph.D. He also is an associate professor of medicine (hematology/medical oncology), OHSU School of Medicine and a Scholar of the Leukemia & Lymphoma Society.

Researchers also discovered that CYT387 effectively blocks overproduction of inflammatory cytokines. Abnormal cells carrying the JAK2-V617F mutation produce a large amount of different inflammatory cytokines that help the cancer cells to grow and repress normal cells. In mice, the drug normalized 19 different inflammatory cytokine levels in the blood. The overproduction of cytokines can also be found in inflammatory conditions such as rheumatoid arthritis. This drug's effect on cytokines could benefit patients with inflammatory diseases, especially rheumatoid arthritis.

The next likely step will be to open clinical trials for people with MPD as soon as 2009 once formal preclinical toxicology studies are completed.

Source: Oregon Health & Science University

Explore further: Cancer patients need anxiety, depression screening

add to favorites email to friend print save as pdf

Related Stories

The anti-inflammatory factory

21 hours ago

Russian scientists, in collaboration with their colleagues from Pittsburgh University, have discovered how lipid mediators are produced. The relevant paper was published in Nature Chemistry. Lipid mediators are molecules that p ...

A closer look into the TSLP cytokine structure

Apr 04, 2014

The PROXIMA 2 beamline at Synchrotron SOLEIL recently celebrated its first birthday. It's an occasion to reflect back upon a year of the collaborative work accomplished and its high scientific impact. In ...

Nanoparticles target anti-inflammatory drugs where needed

Feb 23, 2014

Researchers at the University of Illinois at Chicago have developed a system for precisely delivering anti-inflammatory drugs to immune cells gone out of control, while sparing their well-behaved counterparts. ...

Gene prevents buildup of misfolded cell proteins

Jan 24, 2014

(Phys.org) —Much like how a snowplow is needed to clear streets of heavy snow, cells employ a set of genes to clear away misfolded proteins, to prevent them from accumulating and destroying the cell.

Recommended for you

Cancer patients need anxiety, depression screening

11 hours ago

(HealthDay)—It is important to recognize and treat anxiety or depression among cancer patients, according to a clinical guideline published online April 14 in the Journal of Clinical Oncology.

Pre-HPV vaccine, most oropharyngeal cancers HPV+

12 hours ago

(HealthDay)—Most oropharyngeal cancers in the United States diagnosed between 1995 and 2005 were positive for human papillomavirus (HPV), specifically HPV 16 or 18, according to a study published in the May issue of the ...

'Dustman' protein helps bin cancer cells

Apr 21, 2014

Cancer researchers have discovered a new 'dustman' role for a molecule that helps a drug kill cancer cells according to a study, published in the journal Proceedings of the National Academy of Sciences (PNAS) ...

User comments : 0

More news stories

Saudi announces 11 new MERS infections

Saudi Arabia on Wednesday announced 11 new cases of MERS, including a 13-year-old child, as its acting health minister vowed to keep the public better informed on the coronavirus.

Volitional control from optical signals

(Medical Xpress)—In their quest to build better BMIs, or brain-machine-interfaces, researchers have recently begun to look closer at the sub-threshold activity of neurons. The reason for this trend is that ...

60% of China underground water polluted: report

Sixty percent of underground water in China which is officially monitored is too polluted to drink directly, state media have reported, underlining the country's grave environmental problems.